Menu Back toLS03: 5 Industry Group Joint Session:New Options in Clinical Trial Operation Model?DCT & Remote Utilization (Part 1)

18th DIA Japan Annual Meeting 2021

All prices are exclusive of 10% Japanese consumption tax

LS03: 5 Industry Group Joint Session:New Options in Clinical Trial Operation Model?DCT & Remote Utilization (Part 1)

Session Chair(s)

Hiroshi  Matsuzawa, MSc

Hiroshi Matsuzawa, MSc

  • Clinical Development
  • Astellas Pharma Inc., Japan
Toshiharu  Sano, RPh

Toshiharu Sano, RPh

  • Executive Director, Japan Development
  • MSD K.K., Japan

Speaker(s)

Ai  Nakamura

Ai Nakamura

  • Performance Working Group Member
  • R&D Head Club, Japan
Takeshi  Hashimoto, MPharm

Takeshi Hashimoto, MPharm

  • Co-leader
  • Novartis Pharma K.K., Japan
Masahito  Yamanaka

Masahito Yamanaka

  • Taskforce Member
  • EFPIA (Bayer Yakuhin, Ltd.), Japan
Junichi  Tanokashira

Junichi Tanokashira

  • Clinical Evaluation Expert Committee, Drug Evaluation Committee
  • Japan Pharmaceutical Manufacturers Association (JPMA), Japan

Contact us